Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Incyte

< Previous 1 2 3 4 Next >
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
From Incyte
Via Business Wire
Tickers INCY
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
From Incyte
Via Business Wire
Tickers INCY
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
Incyte Provides Update on Parsaclisib and MCLA-145
From Incyte
Via Business Wire
Tickers INCY
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
From Incyte
Via Business Wire
Tickers INCY MOR
Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo
From Incyte
Via Business Wire
Tickers INCY
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
From Incyte
Via Business Wire
Tickers INCY
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback